SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

29 Jul 2022 Evaluate
The sales declined to Rs. 31571.30 millions for the June 2022 quarter as compared to Rs. 35106.70 millions during the corresponding quarter last year.The Company's Net profit for the June 2022 quarter have declined marginally to Rs. 6440.00  millions as against Rs. 7885.10 millions reported during the corresponding quarter ended.Operating profit for the quarter ended June 2022 decreased to 9750.60 millions as compared to 11977.80 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 31571.30 35106.70 -10.07 31571.30 35106.70 -10.07 130917.90 113027.10 15.83
Other Income 1176.80 796.60 47.73 1176.80 796.60 47.73 6667.00 2302.80 189.52
PBIDT 9750.60 11977.80 -18.59 9750.60 11977.80 -18.59 40331.70 32976.90 22.30
Interest 22.10 80.00 -72.38 22.10 80.00 -72.38 269.30 450.70 -40.25
PBDT 9728.50 11897.80 -18.23 9728.50 11897.80 -18.23 40062.40 32526.20 23.17
Depreciation 1074.60 1139.70 -5.71 1074.60 1139.70 -5.71 4600.10 4686.20 -1.84
PBT 8653.90 10758.10 -19.56 8653.90 10758.10 -19.56 35462.30 27840.00 27.38
TAX 2213.90 2873.00 -22.94 2213.90 2873.00 -22.94 8568.40 7393.50 15.89
Deferred Tax -112.50 -89.30 25.98 -112.50 -89.30 25.98 -304.00 -169.20 79.67
PAT 6440.00 7885.10 -18.33 6440.00 7885.10 -18.33 26893.90 20446.50 31.53
Equity 1613.80 1613.20 0.04 1613.80 1613.20 0.04 1613.60 1612.90 0.04
PBIDTM(%) 30.88 34.12 -9.48 30.88 34.12 -9.48 30.81 29.18 5.59

Cipla Share Price

1238.35 0.05 (0.00%)
20-Apr-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.95
Dr. Reddys Lab 1236.00
Cipla 1238.35
Zydus Lifesciences 942.05
Lupin 2330.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×